This ADC product is comprised of an anti-EGFR monoclonal antibody conjugated via a Mc-VC-PABC linker to MMAE. The MMAE is targeted to EGFR-positive cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten